Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to -$9.0 million.

  • Rxo's Free Cash Flow rose 5263.16% to -$9.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$8.0 million, marking a year-over-year increase of 8596.49%. This contributed to the annual value of -$8.0 million for FY2025, which is 8596.49% up from last year.
  • As of Q4 2025, Rxo's Free Cash Flow stood at -$9.0 million, which was up 5263.16% from $9.0 million recorded in Q3 2025.
  • Rxo's 5-year Free Cash Flow high stood at $91.0 million for Q1 2022, and its period low was -$19.0 million during Q4 2024.
  • Over the past 5 years, Rxo's median Free Cash Flow value was $8.0 million (recorded in 2023), while the average stood at $14.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 200000.0% in 2024, then soared by 15625.0% in 2025.
  • Rxo's Free Cash Flow (Quarter) stood at $27.0 million in 2021, then surged by 114.81% to $58.0 million in 2022, then crashed by 98.28% to $1.0 million in 2023, then plummeted by 2000.0% to -$19.0 million in 2024, then soared by 52.63% to -$9.0 million in 2025.
  • Its last three reported values are -$9.0 million in Q4 2025, $9.0 million for Q3 2025, and $9.0 million during Q2 2025.